# A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer

> **NCT02138422** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 276 (estimated)

## Conditions studied

- Symptomatic Colorectal Cancer
- Advanced Colorectal Cancer
- Colorectal Cancer With Cachexia

## Interventions

- **BIOLOGICAL:** Xilonix
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02138422
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-31
- **Primary completion:** 2015-11-30
- **Final completion:** 2015-11-30
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2021-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02138422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02138422, "A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02138422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*